Pieris Pharmaceuticals Inc logo

PIRS

Pieris Pharmaceuticals Inc

$1.62

Earnings Summary

Revenue
$3.7Mn
Net Profits
$-10.34Mn
Net Profit Margins
-279.56%

Highlights

Revenue:

Pieris Pharmaceuticals Inc’s revenue jumped 12.57% since last year same period to $3.7Mn in the Q2 2022. On a quarterly growth basis, Pieris Pharmaceuticals Inc has generated -66.35% fall in its revenue since last 3-months.

Net Profits:

Pieris Pharmaceuticals Inc’s net profit jumped 33.29% since last year same period to $-10.34Mn in the Q2 2022. On a quarterly growth basis, Pieris Pharmaceuticals Inc has generated -102.67% fall in its net profits since last 3-months.

Net Profit Margins:

Pieris Pharmaceuticals Inc’s net profit margin jumped 40.74% since last year same period to -279.56% in the Q2 2022. On a quarterly growth basis, Pieris Pharmaceuticals Inc has generated -502.19% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Pieris Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.11
EPS Estimate Current Year
-0.11

Highlights

EPS Estimate Current Quarter:

Pieris Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.11 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Pieris Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.11.

Key Ratios

Key ratios of the Pieris Pharmaceuticals Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.91
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Pieris Pharmaceuticals Inc’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Pieris Pharmaceuticals Inc’s return on equity (ROE) stands at -0.91.

Dividend Per Share (DPS):

Pieris Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-11
-0.11
-0.07
36.36%

Company Information

Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.

Organisation
Pieris Pharmaceuticals Inc
Headquarters
Boston, Massachusetts, US
Employees
117
Industry
Health Technology
CEO
Stephen Yoder